Curia – Springfield, MO, USA
Controlled substance manufacturing from gram to metric ton, with large-scale organometallic and cryogenic chemistry.
Curia’s Springfield facility specializes in manufacturing controlled active pharmaceutical substances in Schedule I through V categories and in large-scale synthesis, including organometallic reagent handling, cryogenic reactions to -100 °C and large-scale fractional distillation across two manufacturing facilities.
Facility at a glance
Expertise
115+ experts
An experienced technical and operations team focused on controlled and large-scale API manufacture.
Reactor capacity
120 to 6,000 L
A flexible reactor fleet spans development quantities through large-scale commercial batches.
Cryogenic scale
-100 °C at 9,800 L
Cryogenic chemistry at reaction temperatures as low as -100 °C at 9,800 L scale.
Organometallics
7,600 to 22,700 L
Custom Grignard reagent manufacture at 7,600 L scale, with organometallic handling to 22,700 L.
Compliance
FDA inspected
FDA inspection history supports regulated commercial API supply from a US site.
What this site does
Schedule I-V manufacture from gram to metric ton
Springfield manufactures Schedule I-V controlled substances at scales from grams to metric tons, giving sponsors a US-based, DEA-regulated source for scheduled APIs across the full range of program sizes.
Two facilities for 500 to 1,000 kg batches
Two manufacturing facilities at Springfield produce batches in the 500 to 1,000 kg range, with centrifugation isolation and a cone dryer supporting large-scale isolation and drying.
Custom Grignard reagents at production scale
The site manufactures custom Grignard reagents at 7,600 L scale and handles organometallics at 7,600 to 22,700 L scale, supplying them in drums or cylinders for use on site or beyond.
Deep-temperature chemistry at 9,800 L
Large-scale cryogenic capability supports reaction temperatures as low as -100 °C at 9,800 L scale, enabling low-temperature chemistry that few sites can run at production volume.
Large-scale purification of liquid products
A packed-column fractional distillation system capable of partial reflux and take-off purifies liquid products at 2,500 to 4,000 kg scale, keeping high-purity isolation in-house.
Why clients love this site
Full-spectrum controlled substance capability
Schedule I through V manufacturing at gram to metric ton scales covers regulated programs from development through commercial supply.
Chemistry others can’t run at scale
Cryogenic reactions at -100 °C and organometallic handling at up to 22,700 L put demanding chemistry within reach at production volume.
Batch sizes matched to commercial demand
Two facilities produce 500 to 1,000 kg batches with centrifugation isolation and cone drying.
Reliable US-based supply
An FDA-inspected US site de-risks supply chains for sponsors seeking Western manufacture of complex and controlled APIs.
How this site fits into Curia’s network
Rensselaer pairs Schedule I-V licensing with highly potent compound production from grams to 120 kg and roughly 180,000 L of reactor capacity, complementing Springfield within Curia’s US controlled substance network.
Albany provides phase-appropriate process development, DEA-registered clinical manufacture and Curia’s analytical center, developing the processes that scale into Springfield’s large-scale facilities.
Bon-Encontre offers continuous flow chemistry, scale-up to commercial tons and controlled substance handling, giving programs a European counterpart for large-scale synthesis.
Frankfurt contributes complex starting materials, hydrogenation and high-performance distillation, supporting the upstream supply chain for Springfield’s manufacturing programs.